Anika Therapeutics | ANIK - Cost Of Sales

Stock Price
16.00
Daily Change
0.61 3.96%
Monthly
13.39%
Yearly
14.04%
Q2 Forecast
15.65

Anika Therapeutics reported $11.44M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Abbott USD 5.3B 380M Mar/2026
Agenus USD 642K 399K Sep/2025
Agios Pharmaceuticals USD 1.88M 199K Dec/2025
Anika Therapeutics USD 11.44M 797K Dec/2025
Halozyme Therapeutics USD 102.15M 29.14M Dec/2025
Heron Therapeutics USD 11.12M 795K Dec/2025
Insmed USD 46.16M 15.25M Dec/2025
Integra LifeSciences USD 193.44M 1.62M Dec/2025
Intrexon USD 1.01M 344K Jun/2024
J&J USD 8.07B 103M Mar/2026
Karyopharm Therapeutics USD 1.48M 35.95M Dec/2025
Ligand Pharmaceuticals USD 11.9M 733K Sep/2025
MacroGenics USD 10.12M 34.18M Dec/2025
Merit Medical Systems USD 198.58M 838K Dec/2025
Rigel Pharmaceuticals USD 8.03M 5.22M Sep/2024
Sangamo BioSciences 2.42M 1.11M Jun/2024
Sanofi EUR 4.29B 421M Dec/2025
Smith & Nephew USD 870M 17M Dec/2025
Stryker USD 2.69B 373M Dec/2025
Surmodics USD 9.49M 23.54M Jun/2025
Veracyte USD 39.28M 1.93M Dec/2025
Xencor USD 61.66M 50.95M Jun/2025
Zimmer Biomet Holdings USD 970.1M 234.3M Dec/2025